Nintedanib esylate

FDA Drug Profile — Nintedanib esylate

Nintedanib esylate is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Nintedanib esylate. Available dosage forms: capsule, powder.

Drug details

Generic Name
Nintedanib esylate
Brand Names
Nintedanib esylate
Application Number
ANDA219926
Sponsor
Macleods Pharmaceuticals Limited
NDC Codes
3
Dosage Forms
CAPSULE, POWDER
Routes
ORAL
Active Ingredients
NINTEDANIB ESYLATE

Indications and Usage

1 INDICATIONS & USAGE Nintedanib capsules are kinase inhibitor indicated in adults for: • Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) • Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) 1.1 Idiopathic Pulmonary Fibrosis Nintedanib capsules are indicated for the treatment of adults with idiopathic pulmonary fibrosis (IPF). 1.2 Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype Nintedanib capsules are indicated for the treatment of adults with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype [see Clinical Studies ( 14.2 )].

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.